rewrite this title Twist Biosciences: Keeping Synthetic Biology Alive – Nanalyze

Remember synthetic biology? It was a technology platform that would allow mankind to play God. Not long after Craig Venter created the first synthetic life form in 2010, synthetic biology darling Intrexxon went public making its prolific founder an instant billionaire. The company ended up quietly fading away into oblivion, but then another high profile synthetic biology company had investors screaming from the rooftops.

We consistently warned investors over the years about Ginkgo Bioworks $DNA which had more red flags than a Chinese military parade, not the least of which was two founders clearing a cool $750 million in compensation between the two. The company is worth about half that amount these days as their revenues continue to sink as each year passes. Despite all the failed synthetic biology stories out there, one has stood the test of time – Twist Biosciences $TWST.

What Does Twist Do?

Twist breaks down their business into two divisions: DNA synthesis and protein solutions and NGS applications.

The former involves selling synthesized DNA and RNA to researchers and pharma companies for things like material creation or drug development. The latter stands for “next-generation sequencing,” and it involves selling t